Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas B. Johnson(Vanderbilt University Medical Center), Javid J. Moslehi(Cardiovascular Institute of the South), Daniel S. Reshef(Bristol-Myers Squibb (Germany)), Nina Kola(Bristol-Myers Squibb (Germany)), Benjamin A. Olenchock(Regeneron (United States)), Spyridon Chalkias(Institute of Neuroimmunology of the Slovak Academy of Sciences), Yaomin Xu(Vanderbilt University Medical Center), Mellissa Hicks(Jisc), Jonathan G. Seidman(Harvard University), Robert A. Anders(Johns Hopkins University), Igor J. Koralnik(Northwestern University), Janis M. Taube(Bloomberg (United States)), David Slosky(Jisc), Igor Puzanov(Roswell Park Comprehensive Cancer Center), Luis A. Díaz(Memorial Sloan Kettering Cancer Center), Jonathan S. Deutsch(Bristol-Myers Squibb (Germany)), Mark A. Pilkinton(Tulane University), Raquel P. Deering(Regeneron (United States)), Laura Deeanne Craig-Owens(Bipar), Dan M. Roden(Garvan Institute of Medical Research), Jason R. Becker(University of Pittsburgh), Matthew R. Alexander(Jisc), Jeffrey A. Sosman(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Tyler Bloomer(Jisc), Elizabeth J. Phillips(Murdoch University), Margaret Compton(Bipar), Justin M. Balko(Vanderbilt University Medical Center), Robert Hoffman(Bipar), Gregory E. Plautz(Bristol-Myers Squibb (Germany)), Joshua Gorham(Harvard University), Andrew H. Lichtman(Brigham and Women's Hospital), Christine E. Seidman(Harvard University)
Cited by 2,280
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Cancer Genome Landscapes
|Science|2013|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k